Evaluation of Immunogenicity and Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine

PHASE3CompletedINTERVENTIONAL

Enrollment

321

Participants

Timeline

Start Date

November 30, 1993

Primary Completion Date

April 30, 1995

Study Completion Date

April 30, 1995

Conditions

Hepatitis B

Interventions

BIOLOGICAL

HBsAg formulated with different concentrations of MPL and Aluminium Salts

Intramuscular injection, 3 doses

BIOLOGICAL

Engerix™-B

Intramuscular injection, 3 doses

Trial Locations (1)

GSK Clinical Trials Call Center, Vienna